Business Context and Reporting Period
Company: Neogen Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: May 31, 2008
Business Overview: Neogen develops, manufactures, and markets products dedicated to food and animal safety. Operations are divided into two primary segments: Food Safety (diagnostic test kits for pathogens, toxins, and allergens) and Animal Safety (pharmaceuticals, rodenticides, vaccines, and veterinary instruments). The company operates manufacturing facilities in the U.S. (Michigan, Kentucky, Wisconsin) and Scotland.
Key Financial Metrics
| Metric | Fiscal 2008 | Fiscal 2007 | Change |
|---|---|---|---|
| Net Sales | $102,418,000 | $86,138,000 | +19% |
| Gross Margin | $53,233,000 (52.0%) | $44,563,000 (51.7%) | +25 bps |
| Operating Income | $18,019,000 | $13,504,000 | +33% |
| Net Income | $12,098,000 | $9,125,000 | +33% |
| Diluted EPS | $0.81 | $0.64 | +27% |
| Cash & Equivalents | $14,270,000 | $13,424,000 | +6% |
| Working Capital | $54,495,000 | $41,060,000 | +33% |
| Long-Term Debt | $0 | $0 | N/A |
Segment Performance (2008):
- Food Safety: $57.7M revenue (56.3% of total); Operating Income $14.2M.
- Animal Safety: $44.8M revenue (43.7% of total); Operating Income $5.0M.
Liquidity: The company maintains a $10 million unsecured revolving line of credit with no borrowings outstanding as of May 31, 2008. Cash provided by operating activities was $7.9 million.
Material Changes vs. Prior Period
- Revenue Growth: Driven by a 13% increase in continuing product sales and contributions from the August 2007 acquisition of Kane Enterprises and the December 2007 acquisition of Rivard Instruments.
- Segment Shifts: Food Safety revenue grew 22%, led by Natural Toxins/Allergens (+15%) and Dry Culture Media (+42%). Animal Safety revenue grew 15%, driven by Veterinary Instruments (+32%), partially offset by declines in Vaccine sales (-25%) and Rodenticides (-6%) due to cyclical market conditions and distributor timing.
- Margin Expansion: Gross margins improved to 52% due to product mix changes, manufacturing efficiencies, and the internal production of ATP sanitation tests. Operating expenses as a percentage of sales decreased from 36% to 34%.
- Balance Sheet: Inventory increased 45% ($8.7M) to support higher sales volumes, new product introductions, and supply chain stability. Accounts receivable increased 30% ($4.5M), with days sales outstanding rising from 54 to 58 days.
Outlook, Risks, and Management Commentary
Management Commentary: Management attributes growth to organic sales expansion, successful acquisitions, and cost controls. R&D expenditures were $3.6 million (3.6% of revenue), with plans to increase this to approximately 5% of revenue in FY-2009 to support new product development.
Guidance: The company does not provide specific financial forecasts. Management expects R&D to remain between 4% and 6% of revenues over time.
Risks and Contingencies:
- Acquisition Integration: Success depends on effectively integrating acquired businesses (Kane, Rivard) and managing growth.
- International Exposure: 38.4% of revenue is international, exposing the company to currency fluctuations (primarily British Pound and Euro) and foreign regulatory changes.
- Intellectual Property: Reliance on patents and trade secrets; risk of infringement litigation or inability to secure licenses.
- Market Cyclicality: Dependence on the agricultural marketplace, which is subject to weather conditions and economic cycles.
- Product Liability: Inherent risks in manufacturing diagnostic and pharmaceutical products.
Unusual Items: No significant unusual items were reported. The company recognized $37,000 in grant income in 2008 (compared to $250,000 in 2006).
Investor Verification Checklist
- Inventory Levels: Verify the rationale for the 45% increase in inventory and assess obsolescence risks given the 45% rise in raw materials and finished goods.
- Accounts Receivable: Monitor the increase in days sales outstanding (54 to 58 days) and the concentration of credit risk (one customer represented 11.9% of total revenue).
- Acquisition Synergies: Evaluate the financial integration and performance of Kane Enterprises and Rivard Instruments in subsequent quarters.
- International Currency: Assess the impact of foreign exchange rate fluctuations on the 38% of revenue generated outside the U.S.
- R&D Pipeline: Confirm the progress of new product introductions planned for fiscal years 2009–2011 to sustain growth.